Genomic Health Receives Average Rating of “Hold” from Brokerages (NASDAQ:GHDX)
Genomic Health (NASDAQ:GHDX) has earned an average recommendation of “Hold” from the ten ratings firms that are covering the stock, Analyst Ratings News reports. Four analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $27.50.
Separately, analysts at Canaccord Genuity reiterated a “hold” rating on shares of Genomic Health in a research note on Monday, August 11th. They now have a $27.00 price target on the stock, down previously from $30.00.
In other Genomic Health news, EVP Steven Shak sold 13,348 shares of Genomic Health stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $27.36, for a total transaction of $365,201.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Genomic Health (NASDAQ:GHDX) opened at 28.60 on Monday. Genomic Health has a 1-year low of $23.90 and a 1-year high of $37.24. The stock’s 50-day moving average is $26.81 and its 200-day moving average is $26.9. The company’s market cap is $901.7 million.
Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.26) by $0.11. The company had revenue of $70.50 million for the quarter, compared to the consensus estimate of $69.04 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts expect that Genomic Health will post $-0.80 EPS for the current fiscal year.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.